Executive at Lexicon (NASDAQ: LXRX) settles tax via share withholding

Rhea-AI Filing Summary

LEXICON PHARMACEUTICALS, INC. senior vice president Lisa DeFrancesco reported equity award activity on common stock. On February 28, 2026, she acquired shares through the exercise and conversion of restricted stock units, including 24,674 and 128,190 units, each representing a right to one common share. A separate transaction disposed of 74,572 common shares at $1.47 per share to satisfy tax withholding obligations, leaving her with directly owned common shares as reported in the filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DeFrancesco Lisa

(Last) (First) (Middle)

2445 TECHNOLOGY FOREST BLVD

11TH FLOOR

(Street)

SPRING TX 77381

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LEXICON PHARMACEUTICALS, INC. [ LXRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, IR and Corp Comm

3. Date of Earliest Transaction (Month/Day/Year)
02/28/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/28/2026		M		24,674	A	(1)	40,251	D
Common Stock	02/28/2026		M		128,190	A	(1)	168,441	D
Common Stock	02/28/2026		F(2)		74,572	D	$1.47	93,869	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(3)	02/28/2026		M			24,674	(4)	(4)	Common Stock	24,674	(1)	24,673	D
Restricted Stock Units	(1)	02/28/2026		M			128,190	(4)	(4)	Common Stock	128,190	(1)	256,380	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of common stock.

2. Withholding of a portion of issued shares by the Company in satisfaction of shareholder's tax withholding obligations with respect thereto.

3. Each restricted stock unit represents a contingent right to receive one share of common stock.

4. Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant.

	/s/ Lisa M. DeFrancesco	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Lexicon Pharmaceuticals (LXRX) report for Lisa DeFrancesco?

Lisa DeFrancesco reported equity award activity involving restricted stock units and common stock. She exercised and converted restricted stock units into common shares, and a portion of those shares was withheld by the company to cover tax obligations, as reflected in the Form 4 filing details.

How many restricted stock units did Lisa DeFrancesco convert at Lexicon Pharmaceuticals (LXRX)?

Lisa DeFrancesco converted 24,674 and 128,190 restricted stock units into common stock. Each restricted stock unit represents a contingent right to receive one share of Lexicon common stock, according to the filing footnotes describing the structure of these equity awards and their settlement terms.

What was the nature of the tax-related share disposition for Lexicon Pharmaceuticals (LXRX)?

The filing shows a disposition of 74,572 common shares at $1.47 per share coded as “F.” This represents withholding of issued shares by the company to satisfy the shareholder’s tax withholding obligations related to the equity award settlement, not an open-market sale transaction.

How do restricted stock units work in this Lexicon Pharmaceuticals (LXRX) Form 4?

Each restricted stock unit grants a contingent right to receive one common share. The footnotes state these units vest in thirds on February 28 of each of the three years following the year of grant, and then settle in common stock upon vesting and conversion.

What vesting schedule applies to Lisa DeFrancesco’s restricted stock units at Lexicon Pharmaceuticals (LXRX)?

The restricted stock units vest in three equal installments. One-third of the shares vest on February 28 of each of the three years following the year in which the grant was made, as outlined in the footnote describing the RSU vesting terms in the Form 4.